Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2019-03-11 Notice of Dividend Amou…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Update - Dividend/Distribution - MVP 4 pages 34.8KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about a dividend payment, including dividend type, amount, record date, payment date, franking details, and dividend reinvestment plan (DRP) specifics. It is an announcement providing shareholders with details about the dividend payment rather than a full financial report or earnings release. The content matches the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and related details for shareholders.
2019-03-11 English
CEO Roadshow Presentation 39 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Medical Developments International dated March 2019. It contains forward-looking statements, strategic goals, product information (Penthrox), market expansion plans, clinical program details, and financial investment figures. The content is structured as a presentation with slides, including sales growth, regulatory updates, and clinical trial progress. There is no indication that this is a formal annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a regulatory filing or voting announcement. The presence of forward-looking statements, strategic and financial highlights, and detailed product and market information strongly suggests this is an investor presentation. The length (15,000 characters) and detailed content support this classification rather than a brief factsheet or announcement. Therefore, the document best fits the category of Investor Presentation (IP).
2019-03-03 English
Change of Director's Interest Notice 2 pages 153.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including the number of shares acquired and disposed, dates of changes, and nature of the interest. This is a report of personal share transactions by a company director. The document length is 3399 characters, which is typical for such notices. There is no financial performance data, earnings information, or management discussion. Therefore, this document fits the definition of a Director's Dealing report.
2019-02-24 English
FY19 Half Year Report and Accounts 23 pages 2.7MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial and operational report for the six months ended 31 December 2018 (H1FY19). It includes comprehensive financial data such as gross revenue, net profit after tax, EBITDA, sales growth percentages, regulatory approvals, clinical and commercial developments, and outlook. The presence of half-year financial results and substantive financial data indicates this is an interim or quarterly report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or presentation. There is no indication that this is an annual report, audit report, or earnings release. The detailed financial and operational information aligns with the definition of an Interim / Quarterly Report (IR). H1 2019
2019-02-19 English
Dividend/Distribution - MVP 4 pages 34.9KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about a dividend payment, including the dividend amount, ex-date, record date, payment date, and details about the Dividend Reinvestment Plan (DRP). It specifies the security on which the distribution will be paid and provides dates and amounts related to the dividend. There is no indication that this is a full financial report or an announcement of a report publication. The content matches the definition of a Notice of Dividend Amount, which announces dividend amounts, payment dates, and details for shareholders.
2019-02-19 English
Appendix 3B 12 pages 368.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, terms of the securities, issue price, purpose of the issue, and compliance with ASX listing rules. It also includes calculations related to placement capacity under ASX rules 7.1 and 7.1A. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding the issuance of new shares/options and the application for quotation of these additional securities. There is no financial performance data, management discussion, or audit information. The content clearly fits the category of a capital or financing update related to new share issuance and capital structure changes.
2019-01-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.